23 completed, 6 recruiting, 5 active not recruiting, 4 unknown. 18 Phase 3, 14 Phase 2, 4 Phase 1, 3 Not applicable, 2 Phase 4.
Follow Prurigo Nodularis: new trials by email Literature Review of Prurigo Nodularis trials Research Report on Prurigo Nodularis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults Prurigo Nodularis | Recruiting | Galderma R&D | 600 | 2025-08-11 | 2026-09-09 | |
| Efficacy of Topical Cannabidiol for Eczema Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream - Chronic Pruritus, Eczema | Phase 2 | Enrolling by invitation | Khon Kaen University | 60 | 2025-05-01 | 2026-08-04 |
| Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis Placebo - Prurigo Nodularis | Phase 3 | Recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 160 | 2025-02-26 | 2025-04-18 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Povorcitinib, Placebo - Prurigo Nodularis | Phase 3 | Active not recruiting | Incyte Corporation | 349 | 2024-10-10 | 2026-05-28 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Povorcitinib, Placebo - Prurigo Nodularis | Phase 3 | Active not recruiting | Incyte Corporation | 346 | 2024-10-10 | 2026-04-14 |
| Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis SHR-1819 Injection, SHR-1819 Injection Placebo - Prurigo Nodularis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 423 | 2024-09-19 | 2026-04-29 |
| A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Rocatinlimab, Placebo - Prurigo Nodularis | Phase 3 | Terminated | Amgen | 469 | 2024-07-18 | 2026-07-27 |
| Study on the Treatment of Prurigo Nodularis With Stapokibart Injection Stapokibart, Placebo - Prurigo Nodularis | Phase 3 | Completed | Keymed Biosciences Co.Ltd | 200 | 2024-06-25 | 2026-06-02 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases BGB-45035, Placebo - Healthy Participants, Healthy Subjects | Phase 1 | Completed | BeiGene | 203 | 2024-06-20 | 2026-06-22 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis Dupilumab - Prurigo Nodularis | Phase 3 | Recruiting | Sanofi | 18 | 2024-05-15 | 2026-10-13 |
| Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis Tofacitinib 5 MG - Prurigo Nodularis, Itch | Not applicable | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 24 | 2024-05-01 | 2024-04-01 |
| A Study of Barzolvolimab in Patients With Prurigo Nodularis barzolvolimab, Matching Placebo - Prurigo Nodularis | Phase 2 | Active not recruiting | Celldex Therapeutics | 140 | 2024-04-12 | 2026-08-04 |
| Upadacitinib for Prurigo Nodularis Upadacitinib - Prurigo Nodularis | Phase 4 | Terminated | Psoriasis Treatment Center of Central New Jersey | 5 | 2024-04-09 | 2026-05-20 |
| Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life EMD Protocol for Urge, Care as Usual - Atopic Dermatitis, Prurigo Nodularis | Not applicable | Completed | Tamar Nijsten | 96 | 2024-03-11 | 2025-11-21 |
| A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream Ruxolitinib Cream 1.5% - Prurigo Nodularis | Phase 1 | Completed | Incyte Corporation | 23 | 2024-02-27 | 2025-08-13 |
| A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine Dupilumab SAR231893 (REGN668) - Prurigo Nodularis | Active not recruiting | Sanofi | 110 | 2023-12-27 | 2026-07-31 | |
| Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study Dupilumab - Prurigo Nodularis | Completed | Sanofi | 110 | 2023-12-12 | 2026-10-01 | |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Ruxolitinib Cream, Vehicle Cream - Prurigo Nodularis | Phase 3 | Completed | Incyte Corporation | 190 | 2023-06-12 | 2026-11-06 |
| Determinants of Chronic Inflammatory Skin Disease Trajectories Topical and systemic drugs - Atopic Dermatitis, Psoriasis | Recruiting | University Hospital Schleswig-Holstein | 1000 | 2023-05-01 | 2026-08-28 | |
| A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 34 | 2022-01-24 | 2024-10-08 |
Showing 20 of 42. Sign in to see all of them.
Pruritus (11) · Dermatitis, Atopic (7) · Prurigo (5) · Skin Diseases (4) · Neurodermatitis (3) · Alopecia Areata (2) · Lichen Planus (2) · Psoriasis (2) · Acne Vulgaris (1) · Autoimmune Diseases (1) · Cicatrix, Hypertrophic (1) · Dermatitis (1) · Dermoid Cyst (1) · Eczema (1) · Granuloma Annulare (1)
Skin and Connective Tissue Diseases (18) · Skin Diseases (14) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (11) · Skin Manifestations (11) · Dermatitis (10) · Skin Diseases, Eczematous (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hypersensitivity (7) · Hypersensitivity, Immediate (7) · Immune System Diseases (7) · Skin Diseases, Genetic (7) · Skin Diseases, Papulosquamous (4) · Alopecia (2)
nemolizumab (5) · serlopitant (4) · dupilumab (3) · Saline Solution (2) · Adrenal Cortex Hormones (1) · BID protein, human (1) · Cannabidiol (1) · Citalopram (1) · Dexetimide (1) · Hydrocortisone (1) · Lidocaine (1) · Nalbuphine (1) · Sugars (1) · Triamcinolone (1) · abrocitinib (1)
Galderma R&D (6) · Incyte Corporation (5) · Vyne Therapeutics Inc. (4) · Sanofi (3) · Trevi Therapeutics (3) · Celldex Therapeutics (2) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · BeiGene (1) · Genentech, Inc. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hadassah Medical Organization (1) · Johns Hopkins University (1) · Keymed Biosciences Co.Ltd (1) · Khon Kaen University (1)
United States (24) · Germany (22) · Poland (17) · Austria (11) · Canada (11) · France (10) · China (8) · South Korea (7) · Spain (7) · Italy (6) · Netherlands (6) · Switzerland (6) · Australia (5) · Belgium (5) · United Kingdom (5)
Brian Drolet, MD (1) · Franz Josef Legat, MD (1) · Jacek Szepietowski, MD, Ph.D (1) · Jianzhong Zhang, Medical Ph.D (1) · Kathleen Butler, MD (1) · Leonieke W Kranenburg, PhD (1) · Neil Korman, M.D.,PhD. (1) · Rick Waalboer-Spuij, MD, PhD (1) · Sascha Gerdes, MD (1) · Shawn G Kwatra, MD (1)
PMID 37888917, PMID 40266487, PMID 32074418, PMID 32936233, PMID 33760691, PMID 34780095, PMID 34908192, PMID 36680419, PMID 36816342, PMID 37615836, PMID 38431766, PMID 38837144, PMID 39602139, PMID 41051123, PMID 41405008, PMID 41405882
2019 (3), 2017 (2), 2016 (1), 2018 (1), 2023 (1)